Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07769268

Efficacy Evaluation of a Cosmetic Product for Facial Hyperpigmentation

This is a single-center, single-blind clinical study designed to evaluate the efficacy of a depigmenting gel cream through clinical, subjective, and instrumental assessments. A total of 40 female participants, aged 30 to 60 years, will be enrolled and followed for 90 days while using the study product.Participants will be assigned to one of two groups. Group I will include 20 participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, representing Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype. Group II will include 20 participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), representing Fitzpatrick skin phototypes II to V.

The study aims to evaluate the product's effectiveness in reducing facial hyperpigmentation and improving skin appearance over the treatment period.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hyperpigmentation Melanosis Melasma (Facial Melasma) Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases

Age range

30 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Grupo Medcin

Osasco, São Paulo, 06023-070, Brazil

Location status: Recruiting

Location contact

Camila Canale

CONTACT

[email protected]

+55 (11) 98343 6952

Sergio Schalka

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female participants aged 30 to 60 years.
  • Group I: Participants with Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype category. Participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines.
  • Group II: Participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), and Fitzpatrick skin phototypes II to V.
  • Willingness to comply with all study procedures and attend scheduled on-site visits and assessments.
  • Willingness to comply with study procedures and be available for remote contact (telehealth) at scheduled times.
  • Ability to understand the study requirements, provide written informed consent, and sign the informed consent form.

Exclusion criteria

  • Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.
  • Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.
  • Skin conditions or marks in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.
  • History of atopic conditions or allergy to cosmetic products.
  • Active skin diseases and/or lesions in the assessment area.
  • Immunosuppression due to medication use or active disease.
  • Uncontrolled endocrine disorders.
  • Relevant medical history or current evidence of alcohol or substance abuse.
  • Known history or suspected intolerance to products of the same category as the study product.
  • Intense sun exposure within 15 days prior to assessment.
  • Aesthetic or dermatological treatments within 4 weeks prior to assessment.
  • Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study.

Treatment and study plan

Blancy Pro

Other

Blancy Pro is a depigmenting gel cream intended to reduce facial hyperpigmentation and improve skin appearance. Participants will use the product for 90 days, and efficacy will be assessed through clinical, subjective, and instrumental evaluations.

Primary outcomes

  1. Change in Facial Hyperpigmentation Assessed by Chromameter (L* Parameter)

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the efficacy of the investigational product in improving facial hyperpigmentation in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through colorimetric measurements obtained using the Chromameter® device. Changes in the L* parameter will be assessed over time, with higher values indicating skin lightening.

Secondary outcomes

  1. Clinical Improvement of Facial Hyperpigmentation Assessed by a 5-Point Scale

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the efficacy of the investigational product in improving facial hyperpigmentation in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through clinical assessment using a 5-point evaluation scale, ranging from 1 (Very Severe) to 5 (Absent). Higher scores indicate less severe pigmentation and a better clinical outcome.

  2. Change in Melasma Severity Assessed by the Modified Melasma Area and Severity Index (mMASI)

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the efficacy of the investigational product in improving melasma in participants diagnosed with melasma using the Modified Melasma Area and Severity Index (mMASI). The mMASI assesses melasma severity across four facial regions: forehead, right malar region, left malar region, and chin, weighted according to their proportional facial areas. Scores range from 0 to 24, with 0 indicating no melasma and 24 indicating the most severe melasma. Higher scores indicate worse disease severity, and lower scores indicate improvement. The mMASI score is calculated using the formula: mMASI = 0.3(AF×PF) + 0.3(AMD×PMD) + 0.3(AME×PME) + 0.1(AM×PM).

  3. Change in the Number of Facial Pigmented Lesions Assessed by VISIA® Imaging System

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the efficacy of the investigational product in reducing the number of facial pigmented lesions in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through image analysis using the VISIA® imaging system (Canfield Software).

  4. Change in Facial Skin Tone Uniformity Assessed by VISIA® Image Analysis

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the efficacy of the investigational product in improving facial skin tone uniformity in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through image analysis using the VISIA® system and Image-Pro Plus software.

  5. Change in Facial Skin Hydration Assessed by Corneometer®

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the ability of the investigational product to improve facial skin hydration in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through instrumental measurements obtained using the Corneometer® device.

  6. Maintenance of Skin pH Assessed by Skin pHmeter®

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the maintenance of skin pH during use of the investigational product in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through instrumental measurements obtained using the Skin pHmeter®.

  7. Maintenance of Skin Barrier Function Assessed by Tewameter®

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the maintenance of skin barrier function during use of the investigational product through instrumental measurements of transepidermal water loss (TEWL) using the Tewameter® device.

  8. Safety of the Investigational Product Under Normal Conditions of Use

    Time frame: Day 30, Day 60, and Day 90

    Evaluation of the safety and tolerability of the investigational product under normal conditions of use in the target population through clinical monitoring of adverse reactions and tolerability assessments.

  9. Participant-Perceived Efficacy and Product Performance Assessed by Subjective Questionnaire

    Time frame: Day 14, Day 30, Day 60, and Day 90

    Evaluation of the perceived efficacy and performance of the investigational product from the participants' perspective using a Likert Scale questionnaire administered under real-world conditions of use. The Likert Scale ranges from "Strongly Disagree" to "Strongly Agree".

  10. Change in Quality of Life Assessed by the MelasQoL Questionnaire

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

    Evaluation of the impact of treatment on the quality of life of participants with melasma using the Melasma Quality of Life Scale (MelasQoL). The MelasQoL assesses the impact of melasma on daily life and well-being using ordered response categories ranging from "Not bothered at all" to "Bothered all of the time." Responses indicating less bother reflect better quality of life, while responses indicating greater bother reflect worse quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Beatriz Santos Arnoni

CONTACT

[email protected]

+55 (11) 94742 3610

Sponsors and collaborators

Lead sponsor

Brainfarma Industria Química e Farmacêutica S/A

Industry

Registry information

Official study title

Evaluation of the Efficacy of a Cosmetic Product for the Reduction of Facial Hyperpigmentation: A Clinical, Subjective, and Instrumental Study

Acronym: HYPERPIG

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 17, 2026
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.